VBeam Prima (pulsing laser)

2018: Recognition by a safe and effective method of treatment of a rozatse

In May, 2018 in one-center clinical trial of 20 patients use of the pulsing laser on VBeam Prima dyes of Syneron Candela company with a beam with a diameter of 15 mm was recognized safe and effective for treatment of a rozatse.

The last achievements in laser technologies allow to increase emission of energy by 50% and to considerably prolong dye service life, - doctor Eric F. Bernstein, the director of the Center of laser surgery in Ardmore reported, the State of Pennsylvania. – Increase in diameter of a beam up to 15 mm – that increases the area of processing by 125% in comparison with a normal beam with a diameter of 10 mm, - reduces duration of medical procedures and, perhaps, increases efficiency of therapy thanks to deeper penetration of laser energy.

Use of the pulsing laser on VBeam Prima dyes with a beam with a diameter of 15 mm was recognized safe and effective for treatment of a rozatse

Results of a research were estimated on expressiveness of inflammatory defeats, an eritema and teleangiektaziya, and security – on the frequency and weight of ghost effects. The prevailing part of patients reported that they "are very happy" with treatment. In 8 weeks of therapy considerable improvement of shared state of skin was noted, the expressiveness of inflammatory defeats, an eritema and teleangiektaziya decreased. The average score of pain made 5.6 on a 10-mark scale while ghost effects which were permitted within 1-3 days without medical intervention included moderate hypostasis, moderated erity and also slight or moderate bruises. Cases of a hyperpegmentation, hypopigmentation, development of bubbles or hems were not noted.

Doctor Bernstein reported that he received a grant from Syneron Candela and Zeltiq companies. Besides, he received consulting services from Syneron Candela and owns an ownership ratio in this company and also worked in the advisory board of Novoxel, Solta, Syneron Candela and Zeltiq companies.^[1]

Notes